Lung Cancer - Multimodality Therapy
The neoadjuvant chemoimmunotherapy pathway has become the standard of care for patients with resectable, locally advanced non-small cell lung cancer without actionable mutations. Its increasing use has introduced novel technical challenges, as fibrotic changes, inflammatory...
The neoadjuvant chemoimmunotherapy pathway has become the standard of care for patients with resectable, locally advanced non-small cell lung cancer without actionable mutations. Its increasing use has introduced novel technical...
…This week on The Beat, CTSNet Editor-in-Chief Joel Dunning spoke with James Cox, Professor of Cardiac Surgery at the Feinberg School of Medicine at Northwestern Medicine in Chicago, Illinois, USA,...
In this Memorial Sloan Kettering series, 11 patients with metastatic DLL3-high pulmonary carcinoid received the DLL3/CD3 bispecific T-cell engager tarlatamab. Eight patients (73 percent) achieved an objective response; all had...
This study reviews 44 patients with stage IB (larger than 4 cm) to IIIA non-small cell lung cancer who were treated on sequential platform arms of the NEOSTAR trial. Twenty-two...
